PL3233803T3 - Sposób wytwarzania związku diarylotiohydantoiny - Google Patents

Sposób wytwarzania związku diarylotiohydantoiny

Info

Publication number
PL3233803T3
PL3233803T3 PL15823875T PL15823875T PL3233803T3 PL 3233803 T3 PL3233803 T3 PL 3233803T3 PL 15823875 T PL15823875 T PL 15823875T PL 15823875 T PL15823875 T PL 15823875T PL 3233803 T3 PL3233803 T3 PL 3233803T3
Authority
PL
Poland
Prior art keywords
preparation
diarylthiohydantoin compound
diarylthiohydantoin
compound
Prior art date
Application number
PL15823875T
Other languages
English (en)
Polish (pl)
Inventor
Cyril Ben HAIM
Andras Horvath
Johan Erwin Edmond Weerts
Original Assignee
Aragon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aragon Pharmaceuticals, Inc. filed Critical Aragon Pharmaceuticals, Inc.
Publication of PL3233803T3 publication Critical patent/PL3233803T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/14—Phosphorus; Compounds thereof
    • B01J27/186—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium
    • B01J27/195—Phosphorus; Compounds thereof with arsenic, antimony, bismuth, vanadium, niobium, tantalum, polonium, chromium, molybdenum, tungsten, manganese, technetium or rhenium with vanadium, niobium or tantalum
    • B01J27/198—Vanadium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J37/00—Processes, in general, for preparing catalysts; Processes, in general, for activation of catalysts
    • B01J37/04—Mixing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
PL15823875T 2014-12-19 2015-12-17 Sposób wytwarzania związku diarylotiohydantoiny PL3233803T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462094436P 2014-12-19 2014-12-19
PCT/US2015/066356 WO2016100652A2 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound
EP15823875.8A EP3233803B1 (en) 2014-12-19 2015-12-17 Process for the preparation of a diarylthiohydantoin compound

Publications (1)

Publication Number Publication Date
PL3233803T3 true PL3233803T3 (pl) 2019-07-31

Family

ID=55168400

Family Applications (3)

Application Number Title Priority Date Filing Date
PL15823875T PL3233803T3 (pl) 2014-12-19 2015-12-17 Sposób wytwarzania związku diarylotiohydantoiny
PL18169895.2T PL3372585T3 (pl) 2014-12-19 2015-12-17 Sposób wytwarzania związku diarylotiohydantoiny
PL18169756T PL3372584T3 (pl) 2014-12-19 2015-12-17 Sposób wytwarzania związku diarylotiohydantoiny

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL18169895.2T PL3372585T3 (pl) 2014-12-19 2015-12-17 Sposób wytwarzania związku diarylotiohydantoiny
PL18169756T PL3372584T3 (pl) 2014-12-19 2015-12-17 Sposób wytwarzania związku diarylotiohydantoiny

Country Status (34)

Country Link
US (1) US9688655B2 (enExample)
EP (4) EP3233803B1 (enExample)
JP (2) JP6681902B2 (enExample)
KR (1) KR102586059B1 (enExample)
CN (2) CN118638097A (enExample)
AR (1) AR103228A1 (enExample)
AU (1) AU2015364537B2 (enExample)
BR (1) BR112017013113B1 (enExample)
CA (1) CA2970937A1 (enExample)
CY (3) CY1121684T1 (enExample)
DK (3) DK3372585T3 (enExample)
EA (4) EA201791390A1 (enExample)
ES (3) ES2718539T3 (enExample)
HR (3) HRP20190540T1 (enExample)
HU (2) HUE052475T2 (enExample)
IL (1) IL252843B2 (enExample)
LT (3) LT3372584T (enExample)
MA (1) MA41200B1 (enExample)
MD (1) MD3233803T2 (enExample)
ME (1) ME03420B (enExample)
MX (1) MX375467B (enExample)
NZ (1) NZ732766A (enExample)
PH (1) PH12017501152B1 (enExample)
PL (3) PL3233803T3 (enExample)
PT (3) PT3233803T (enExample)
RS (3) RS58454B1 (enExample)
SG (4) SG10201912805SA (enExample)
SI (3) SI3233803T1 (enExample)
SM (3) SMT201900208T1 (enExample)
TR (1) TR201904739T4 (enExample)
TW (4) TWI753336B (enExample)
UA (1) UA123201C2 (enExample)
WO (1) WO2016100652A2 (enExample)
ZA (1) ZA201704877B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3233803T3 (pl) * 2014-12-19 2019-07-31 Aragon Pharmaceuticals, Inc. Sposób wytwarzania związku diarylotiohydantoiny
SG10201907094QA (en) * 2014-12-19 2019-09-27 Aragon Pharmaceuticals Inc Processes for the preparation of a diarylthiohydantoin compound
CN108069869B (zh) * 2016-11-09 2022-03-01 上海医药工业研究院 一种Apalutamide的制备方法及其中间体
TW201831461A (zh) * 2017-01-18 2018-09-01 台灣神隆股份有限公司 製備阿帕魯醯胺的方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN107501237B (zh) * 2017-08-17 2022-03-22 上海西浦医药科技有限公司 一种Apalutamide的合成方法
CN108383749B (zh) * 2018-01-30 2021-03-09 杭州科巢生物科技有限公司 阿帕鲁胺的合成方法及其中间体
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CN108314646B (zh) * 2018-04-11 2021-03-19 武汉慧敏科技中心 一种高分散双金属纳米材料制备泌尿生殖系统用药物中间体的方法
CN109651256A (zh) * 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN110511207A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN110511206A (zh) * 2019-06-17 2019-11-29 扬子江药业集团江苏海慈生物药业有限公司 芳基-2-硫代海因类化合物中间体、其制备方法及应用
CN113968815B (zh) * 2020-07-24 2025-11-18 苏州科伦药物研究有限公司 一种硫代二氮杂螺类化合物的合成方法、其中间体及其合成方法
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
JP2023550386A (ja) 2020-11-20 2023-12-01 アムジエン・インコーポレーテツド ７－クロロ－６－フルオロ－１－（２－イソプロピル－４－メチルピリジン－３－イル）ピリド［２，３－ｄ］ピリミジン－２，４（１Ｈ，３Ｈ）－ジオンを調製するためのプロセス
CN113402466B (zh) * 2021-06-18 2022-08-16 南京方生和医药科技有限公司 一种阿帕鲁胺中间体及制备阿帕鲁胺的方法
CN113292535B (zh) * 2021-06-18 2022-07-01 南京方生和医药科技有限公司 一种制备阿帕鲁胺中间体及阿帕鲁胺的方法
CN115572264B (zh) * 2021-07-06 2025-12-05 山东新时代药业有限公司 一种恩杂鲁胺的制备方法
CN115850233B (zh) * 2021-09-24 2024-12-10 南京方生和医药科技有限公司 一种阿帕鲁胺的合成方法
CN116239536A (zh) * 2021-12-08 2023-06-09 山东新时代药业有限公司 一种阿帕鲁胺中间体化合物
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
CN117645572A (zh) * 2023-11-23 2024-03-05 奥锐特药业股份有限公司 恩扎卢胺及其中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
PL3412290T3 (pl) * 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
WO2009140624A2 (en) * 2008-05-16 2009-11-19 Takeda San Diego, Inc. Glucokinase activators
BR112012015868A2 (pt) * 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
EA028869B1 (ru) * 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
EP2538785B1 (en) * 2010-02-24 2018-03-21 Medivation Prostate Therapeutics LLC Processes for the synthesis of diarylthiohydantoin and diarylhydantoin compounds
CA2829322C (en) * 2011-03-10 2017-01-10 Suzhou Kintor Pharmaceuticals, Inc. Substituted thioimidazolidinone androgen receptor antagonists and uses thereof
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
AU2013240141B2 (en) * 2012-03-29 2017-11-02 Sangart, Inc. Diaspirin crosslinked PEGgylated hemoglobin
AU2014273618B2 (en) * 2013-05-29 2016-10-13 Hinova Pharmaceuticals Inc. Imidazole diketone compound and use thereof
PL3233803T3 (pl) * 2014-12-19 2019-07-31 Aragon Pharmaceuticals, Inc. Sposób wytwarzania związku diarylotiohydantoiny

Also Published As

Publication number Publication date
ME03420B (me) 2020-01-20
CA2970937A1 (en) 2016-06-23
EP3372584B9 (en) 2021-03-31
DK3372584T5 (da) 2021-05-17
SMT202000618T1 (it) 2021-01-05
EP3372585A1 (en) 2018-09-12
HUE052475T2 (hu) 2021-05-28
EP3372584A1 (en) 2018-09-12
US20160176845A1 (en) 2016-06-23
US9688655B2 (en) 2017-06-27
TW201945343A (zh) 2019-12-01
ES2718539T3 (es) 2019-07-02
SI3372585T1 (sl) 2022-08-31
MD3233803T2 (ro) 2019-07-31
RS63455B1 (sr) 2022-08-31
EP3372584B1 (en) 2020-09-23
HRP20201847T2 (hr) 2021-05-28
TWI683810B (zh) 2020-02-01
ES2827549T3 (es) 2021-05-21
MA41200A (fr) 2017-10-25
MA41200B1 (fr) 2019-05-31
CY1125243T1 (el) 2025-03-28
SG10201912802XA (en) 2020-02-27
SI3372584T1 (sl) 2021-08-31
EP3233803A2 (en) 2017-10-25
TWI753336B (zh) 2022-01-21
AU2015364537A1 (en) 2017-07-06
HRP20220750T1 (hr) 2022-09-02
TW201945342A (zh) 2019-12-01
TW202031639A (zh) 2020-09-01
CN107108507B (zh) 2024-05-28
EA201892486A1 (ru) 2019-07-31
PL3372585T3 (pl) 2022-10-10
LT3372584T (lt) 2020-12-10
SI3233803T1 (sl) 2019-05-31
EP3233803B1 (en) 2019-01-30
UA123201C2 (uk) 2021-03-03
EA201892485A1 (ru) 2019-07-31
MX2017008179A (es) 2017-09-18
EP3372585B1 (en) 2022-03-30
PT3372584T (pt) 2020-11-13
ES2919951T3 (es) 2022-07-29
KR102586059B1 (ko) 2023-10-05
DK3372585T3 (da) 2022-05-30
EP3372586A1 (en) 2018-09-12
EA201892487A1 (ru) 2019-07-31
CN118638097A (zh) 2024-09-13
AU2015364537B2 (en) 2020-10-08
TWI689494B (zh) 2020-04-01
IL252843B2 (en) 2025-02-01
ES2827549T9 (es) 2021-07-02
CY1123611T1 (el) 2022-03-24
SG10201912811QA (en) 2020-02-27
CN107108507A (zh) 2017-08-29
CY1121684T1 (el) 2020-07-31
PH12017501152A1 (en) 2017-11-27
PL3372584T3 (pl) 2021-07-05
TR201904739T4 (tr) 2019-05-21
IL252843B1 (en) 2024-10-01
EA201791390A1 (ru) 2017-10-31
TW201639825A (zh) 2016-11-16
SMT201900208T1 (it) 2019-05-10
HUE042409T2 (hu) 2019-06-28
BR112017013113B1 (pt) 2023-11-21
HRP20190540T1 (hr) 2019-06-14
LT3372585T (lt) 2022-07-11
JP2018501237A (ja) 2018-01-18
RS58454B1 (sr) 2019-04-30
KR20170095976A (ko) 2017-08-23
DK3372584T3 (da) 2021-01-04
DK3233803T3 (en) 2019-04-08
LT3233803T (lt) 2019-04-10
RS61060B9 (sr) 2021-07-30
JP6681902B2 (ja) 2020-04-15
MX375467B (es) 2025-03-06
RS61060B1 (sr) 2020-12-31
JP6903785B2 (ja) 2021-07-14
WO2016100652A2 (en) 2016-06-23
AR103228A1 (es) 2017-04-26
ZA201704877B (en) 2019-02-27
PH12017501152B1 (en) 2022-04-29
SG10201912805SA (en) 2020-02-27
PT3372585T (pt) 2022-07-08
JP2020114842A (ja) 2020-07-30
NZ732766A (en) 2023-07-28
WO2016100652A3 (en) 2016-08-25
SMT202200242T1 (it) 2022-07-21
IL252843A0 (en) 2017-08-31
SG11201704969QA (en) 2017-07-28
HRP20201847T1 (hr) 2021-03-19
PT3233803T (pt) 2019-05-20
TWI703132B (zh) 2020-09-01
BR112017013113A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
ZA201704877B (en) Process for the preparation of a diarylthiohydantoin compound
IL281292A (en) Processes for preparing a diarylthiohydantoin compound
IL252912A0 (en) Processes for preparing oxathiazine-like compounds
IL248267A0 (en) A process for preparing converted cycloserines
SG11201704523WA (en) A process for the manufacture of idalopirdine
IL247443B (en) Process for the preparation of 5-fluorotryptophol
EP3174878A4 (en) A process for the preparation of palbociclib
IL252471A0 (en) A process for the production of idalopyridine
LT3393246T (lt) Chelanto gamybos būdas